Clinical Trial Update: Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial assessing the combination of LJM716 and cetuximab for head and neck squamous cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• LJM716

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: WITHDRAWN